by admin | 30th August 2023 | News
Full enrollment anticipated by first week of September OKYO on schedule to release top-line data before end of 2023 Phase 2 trial is designed as potential registration trial with pre-specified primary efficacy endpoints covering both a sign and symptom of DED London...
by admin | 28th July 2023 | News
OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP Second clinical indication for OK-101 which is currently in 240 patient phase 2 clinical... by admin | 2nd May 2023 | News
Trial designed with pre-specified primary efficacy endpoints discussed previously with FDA If successful, this phase 2 trial may serve as one of the two required phase 3 studies necessary to support FDA approval Top-line data from trial anticipated before end of... by admin | 25th April 2023 | News
London and New York, NY, April 25, 2023 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this... by admin | 28th February 2023 | News
OKYO Pharma Limited(“OKYO”, “OKYO Pharma” or the “Company”) OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease London and New York, NY, February 28, 2023 – OKYO Pharma Limited (LSE:...
